首页> 外文期刊>Clinical infectious diseases >Understanding the Promises and Hurdles of Metagenomic Next-Generation Sequencing as a Diagnostic Tool for Infectious Diseases
【24h】

Understanding the Promises and Hurdles of Metagenomic Next-Generation Sequencing as a Diagnostic Tool for Infectious Diseases

机译:了解偏见的下一代测序的承诺和障碍作为传染病的诊断工具

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Agnostic metagenomic next-generation sequencing (mNGS) has emerged as a promising single, universal pathogen detection method for infectious disease diagnostics. This methodology allows for identification and genomic characterization of bacteria, fungi, parasites, and viruses without the need for a priori knowledge of a specific pathogen directly from clinical specimens. Although there are increasing reports of mNGS successes, several hurdles need to be addressed, such as differentiation of colonization from infection, extraneous sources of nucleic acid, method standardization, and data storage, protection, analysis, and interpretation. As more commercial and clinical microbiology laboratories develop mNGS assays, it is important for treating practitioners to understand both the power and limitations of this method as a diagnostic tool for infectious diseases.
机译:无症状的偏心组织下一代测序(MNGs)被出现为有前途的单一,通用病原体检测方法,用于传染病诊断。 该方法允许细菌,真菌,寄生虫和病毒的鉴定和基因组表征,而无需直接从临床标本中先验优先考虑特定病原体。 虽然MNGS成功的报告越来越高,需要解决几个障碍,例如从感染的殖民化,核酸外来源,方法标准化和数据存储,保护,分析和解释等障碍。 随着更多商业和临床微生物学实验室开发MNGS测定,重要的是处理从业者,了解这种方法的功率和局限作为传染病的诊断工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号